GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Capex-to-Revenue

MorphoSys AG (WBO:MOR) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

MorphoSys AG's Capital Expenditure for the three months ended in Dec. 2023 was €0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was €59.08 Mil.

Hence, MorphoSys AG's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


MorphoSys AG Capex-to-Revenue Historical Data

The historical data trend for MorphoSys AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Capex-to-Revenue Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.15 0.15 0.06 0.01

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Competitive Comparison of MorphoSys AG's Capex-to-Revenue

For the Biotechnology subindustry, MorphoSys AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Capex-to-Revenue falls into.



MorphoSys AG Capex-to-Revenue Calculation

MorphoSys AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.873) / 238.278
=0.01

MorphoSys AG's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 59.078
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MorphoSys AG  (WBO:MOR) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


MorphoSys AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (WBO:MOR) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.